NCT06810778 2025-07-15
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT03370185 2023-02-28
BRIO
SecuraBio
Phase 2 Withdrawn
NCT02640833 2016-07-26
A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
AbbVie
Phase 1 Withdrawn
NCT02028039 2014-01-06
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Withdrawn